Randall J Grimshaw, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 200 W Ollie St, Llano, TX 78643 Phone: 325-247-5040 Fax: 325-247-2801 |
Jack P Franklin, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 102 E Young St, Llano, TX 78643 Phone: 325-247-4131 |
Sonja Louise Forrister, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 102 E Young St, Llano, TX 78643 Phone: 325-247-4131 Fax: 325-248-2099 |
Skylar S Forrister, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 102 E Young St, Llano, TX 78643 Phone: 325-247-4131 |
Dan David Hoerster, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 102 E Young St, Llano, TX 78643 Phone: 325-247-4131 Fax: 325-248-2099 |
John Gaston Horner, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 102 W Dallas St, Llano, TX 78643 Phone: 325-216-9072 Fax: 325-399-9064 |
William Christman Ratliff, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 102 E Young St, Llano, TX 78643 Phone: 325-247-4131 |
Janice L Pruessner, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 102 E Young St, Llano, TX 78643 Phone: 325-247-4131 Fax: 325-248-2099 |
News Archive
Exposure to carcinogens in traffic emissions at particular lifetime points may increase the risk of developing breast cancer in women who are lifetime nonsmokers, a study by epidemiologists and geographers at the University at Buffalo has found.
In a healthy immune system, invading pathogens trigger a cascade of alerts and responses to fight off the infection. Sensors called toll-like receptors, or TLRs, act as one of the first lines of defense. Two of these sensors, known as TLR7 and TLR9, specifically recognize and respond to microbial RNA and DNA, respectively. But what determines how these TLRs get where they need to be and sound the alarm for pathogen infection?
Following an infection, dysregulation of the immune system can result in a systemic inflammatory response and an often fatal condition called severe sepsis or septic shock. Sepsis is not uncommon, yet its cause and underlying immune dysfunction remain poorly understood.
Alemtuzumab, an anti-CD52 monoclonal antibody, provides a more effective treatment for individuals with relapsing‑remitting multiple sclerosis than the immunomodulating drug interferon beta 1a, but has significant side effects, show findings from a phase III trial.
› Verified 9 days ago